- Home
- NRIX vs VTLE Comparison
NRIX vs VTLE Comparison
Compare NRIX & VTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- VTLE
- Stock Information
- Founded
- NRIX 2009
- VTLE 2006
- Country
- NRIX United States
- VTLE United States
- Employees
- NRIX N/A
- VTLE N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- VTLE
- Sector
- NRIX Health Care
- VTLE
- Exchange
- NRIX Nasdaq
- VTLE Nasdaq
- Market Cap
- NRIX 728.6M
- VTLE 592.9M
- IPO Year
- NRIX 2020
- VTLE 2011
- Fundamental
- Price
- NRIX $9.91
- VTLE $16.42
- Analyst Decision
- NRIX Strong Buy
- VTLE Hold
- Analyst Count
- NRIX 15
- VTLE 11
- Target Price
- NRIX $29.13
- VTLE $25.67
- AVG Volume (30 Days)
- NRIX 733.8K
- VTLE 2.2M
- Earning Date
- NRIX 10-10-2025
- VTLE 11-05-2025
- Dividend Yield
- NRIX N/A
- VTLE N/A
- EPS Growth
- NRIX N/A
- VTLE N/A
- EPS
- NRIX N/A
- VTLE N/A
- Revenue
- NRIX $88,381,000.00
- VTLE $1,935,411,000.00
- Revenue This Year
- NRIX $74.59
- VTLE $2.60
- Revenue Next Year
- NRIX N/A
- VTLE N/A
- P/E Ratio
- NRIX N/A
- VTLE N/A
- Revenue Growth
- NRIX 41.86
- VTLE 5.26
- 52 Week Low
- NRIX $8.18
- VTLE $12.30
- 52 Week High
- NRIX $29.56
- VTLE $36.72
- Technical
- Relative Strength Index (RSI)
- NRIX 47.82
- VTLE 47.85
- Support Level
- NRIX $8.97
- VTLE $16.70
- Resistance Level
- NRIX $9.68
- VTLE $18.59
- Average True Range (ATR)
- NRIX 0.55
- VTLE 1.14
- MACD
- NRIX 0.04
- VTLE 0.18
- Stochastic Oscillator
- NRIX 55.13
- VTLE 52.36
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.